Details for New Drug Application (NDA): 062750
✉ Email this page to a colleague
NDA 062750 describes PIPRACIL, which is a drug marketed by Wyeth Pharms Inc and is included in two NDAs. Additional details are available on the PIPRACIL profile page.
The generic ingredient in PIPRACIL is piperacillin sodium. There are sixteen drug master file entries for this compound. Additional details are available on the piperacillin sodium profile page.
The generic ingredient in PIPRACIL is piperacillin sodium. There are sixteen drug master file entries for this compound. Additional details are available on the piperacillin sodium profile page.
Summary for 062750
| Tradename: | PIPRACIL |
| Applicant: | Wyeth Pharms Inc |
| Ingredient: | piperacillin sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062750
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 2GM BASE/VIAL | ||||
| Approval Date: | Oct 13, 1987 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 3GM BASE/VIAL | ||||
| Approval Date: | Oct 13, 1987 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 4GM BASE/VIAL | ||||
| Approval Date: | Oct 13, 1987 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
